Furman B L, Tayo F M
Eur J Pharmacol. 1975 Mar;31(1):115-21. doi: 10.1016/0014-2999(75)90084-9.
ICI 66082, a cardioselective beta-adrenoceptor blocking agent, was found to produce hypoglycaemia in fasted rats. In fed rats a hyperglycaemic response was observed. The drug produced hypoglycaemia in fed adrenalectomised animals. The hypoglycaemic response to ICI 66082 was accompanied by elevations in plasma immunoreactive insulin (IRI) concentrations. The drug also reduced plasma glucose and increased IRI in moderately alloxan-diabetic rats. In severely diabetic animals The drug did not increase IRI concentrations and did not unequivocally lower plasma glucose concentrations. In vitro experiments showed ICI 66082 to increase glucose uptake by rat diaphragm muscle and epididymal adipose tissue. the hypoglycaemic response may be mediated by increases in plasms IRI concentrations with a possible contribution from direct effects of the drug on peripheral glucose utilization. As these responses differ from those published in relation to other beta-adrenoceptor blocking drugs it is unlikely that the effects are due to beta-adrenoceptor blockade. However, like other beta-adrenoceptor blocking drugs ICI 66082 reduced isoprenaline-mediated increase in plasma IRI.
ICI 66082是一种心脏选择性β-肾上腺素能受体阻滞剂,被发现可使禁食大鼠产生低血糖。在喂食的大鼠中观察到高血糖反应。该药物在喂食的肾上腺切除动物中产生低血糖。对ICI 66082的低血糖反应伴随着血浆免疫反应性胰岛素(IRI)浓度的升高。该药物还可降低中度四氧嘧啶糖尿病大鼠的血糖并增加IRI。在重度糖尿病动物中,该药物不会增加IRI浓度,也不会明确降低血糖浓度。体外实验表明,ICI 66082可增加大鼠膈肌和附睾脂肪组织对葡萄糖的摄取。低血糖反应可能是由血浆IRI浓度升高介导的,药物对周围葡萄糖利用的直接作用可能也有一定贡献。由于这些反应与其他β-肾上腺素能受体阻滞剂的相关报道不同,因此这些作用不太可能是由于β-肾上腺素能受体阻断所致。然而,与其他β-肾上腺素能受体阻滞剂一样,ICI 66082可降低异丙肾上腺素介导的血浆IRI升高。